keine Finanzberatung

ALNY · Alnylam Pharmaceuticals

RNA-interference therapeutics; Amvuttra and Onpattro for ATTR amyloidosis

Risiko 7/10 · HIGH RISK · single-franchise biotech · $266.11 ▲ 0.61%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $266.11
  • Market cap $35.6B
  • P/E (ttm) 46.28
  • Div yield none
  • 52-wk range $197.81 – $495.55
  • Index rank — / #78

Wichtigste Risiken

  • Amvuttra ATTR-CM launch underdelivers (Shareholders) — EXTREME
  • Head-to-head competition from Pfizer and BridgeBio (Shareholders) — HIGH
  • Guidance credibility shattered by the sales-view cut (Shareholders) — HIGH
  • High leverage for a one-franchise drugmaker (Bondholders) — MED

Fazit

The science is proven; the stock now needs the commercial launch to be, too.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.